ALNOV — Novacyt SA Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Novacyt SA, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	C2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	92.6	21	10.6	19.6	20
Cost of Revenue
Gross Profit	28.2	5.75	3.49	32.1	12.6
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	96.6	44.4	36.1	57	48.5
Operating Profit	-3.98	-23.4	-25.4	-37.3	-28.5
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-5.66	-20.1	-24.5	-39.4	-27.3
Provision for Income Taxes
Net Income After Taxes	-6.01	-22.2	-24.1	-38.7	-23.5
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-9.73	-25.7	-28.3	-41.8	-22.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-9.73	-25.7	-28.3	-41.8	-22.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.037	-0.229	-0.237	-0.341	-0.163
Dividends per Share